THE INFLUENCE OF SUCROSE, DEXTRAN, AND HYDROXYPROPYL-BETA-CYCLODEXTRIN AS LYOPROTECTANTS FOR A FREEZE-DRIED MOUSE IGG2A MONOCLONAL-ANTIBODY (MN12)

被引:46
作者
RESSING, ME
JISKOOT, W
TALSMA, H
VANINGEN, CW
BEUVERY, EC
CROMMELIN, DJA
机构
[1] UNIV UTRECHT,FAC PHARM,DEPT PHARMACEUT,POB 80082,3508 TB UTRECHT,NETHERLANDS
[2] NATL INST PUBL HLTH & ENVIRONM PROTECT,BILTHOVEN,NETHERLANDS
[3] FDN ADVANCEMENT PUBL HLTH & ENVIRONM PROTECT,BILTHOVEN,NETHERLANDS
关键词
MONOCLONAL ANTIBODY; LYOPHILIZATION; FREEZE-DRYING; STABILITY; FORMULATION; CYCLODEXTRIN;
D O I
10.1023/A:1018905927544
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The influence of lyophilization on the stability of a monoclonal antibody (MN12) was investigated. MN12 was freeze-dried in different formulations [without lyoprotectant or in the presence of sucrose, dextran, or hydroxypropyl-beta-cyclodextrin (HP-beta-CD)] and under varying conditions (with or without secondary drying). Subsequently, the monoclonal antibody was stored for 18 or 32 days at various temperatures (4, 37, or 56-degrees-C). For comparison, solutions of MN12 were stored under the same conditions. Regardless of the lyoprotectant used, precipitation and a concomitant reduction of the antigen-binding capacity by about 10% were observed upon reconstitution of lyophilized MN12. HP-beta-CD proved to be the most effective stabilizer to prevent degradation of lyophilized MN12 during storage. Compared with MN12 solutions, HP-beta-CD-containing lyophilized MN12 cakes were more resistant to heat-induced charge alterations and loss of antigen-binding capacity.
引用
收藏
页码:266 / 270
页数:5
相关论文
共 25 条
[1]  
BREWSTER ME, 1989, J PARENT SCI TECHN, V43, P231
[2]   ONE-STEP PURIFICATION OF MOUSE MONOCLONAL-ANTIBODIES FROM ASCITIC FLUID BY DEAE AFFI-GEL BLUE CHROMATOGRAPHY [J].
BRUCK, C ;
PORTETELLE, D ;
GLINEUR, C ;
BOLLEN, A .
JOURNAL OF IMMUNOLOGICAL METHODS, 1982, 53 (03) :313-319
[3]   STABILIZATION OF PHOSPHOFRUCTOKINASE WITH SUGARS DURING FREEZE-DRYING - CHARACTERIZATION OF ENHANCED PROTECTION IN THE PRESENCE OF DIVALENT-CATIONS [J].
CARPENTER, JF ;
CROWE, LM ;
CROWE, JH .
BIOCHIMICA ET BIOPHYSICA ACTA, 1987, 923 (01) :109-115
[4]  
Duchene D., 1990, PHARM TECHNOL, V14, P26
[5]  
DUFFY SA, 1989, BIOPHARM, V2, P34
[6]  
FRANKS F, 1990, CRYO-LETT, V11, P93
[7]  
HELLMAN K, 1983, BIOPHYS ACTA, V743, P133
[8]   2-STEP PURIFICATION OF A MURINE MONOCLONAL-ANTIBODY INTENDED FOR THERAPEUTIC APPLICATION IN MAN - OPTIMIZATION OF PURIFICATION CONDITIONS AND SCALING UP [J].
JISKOOT, W ;
VANHERTROOIJ, JJCC ;
GEBBINCK, WTMK ;
VANDERVELDENDEGROOT, T ;
CROMMELIN, DJA ;
BEUVERY, EC .
JOURNAL OF IMMUNOLOGICAL METHODS, 1989, 124 (01) :143-156
[9]   PREPARATION OF CLINICAL GRADE MONOCLONAL-ANTIBODIES FROM SERUM-CONTAINING CELL-CULTURE SUPERNATANTS [J].
JISKOOT, W ;
VANHERTROOIJ, JJCC ;
HOVEN, AMV ;
GEBBINCK, JWTMK ;
VANDERVELDENDEGROOT, T ;
CROMMELIN, DJA ;
BEUVERY, EC .
JOURNAL OF IMMUNOLOGICAL METHODS, 1991, 138 (02) :273-283
[10]   ANALYTICAL APPROACHES TO THE STUDY OF MONOCLONAL-ANTIBODY STABILITY [J].
JISKOOT, W ;
BEUVERY, EC ;
DEKONING, AAM ;
HERRON, JN ;
CROMMELIN, DJA .
PHARMACEUTICAL RESEARCH, 1990, 7 (12) :1234-1241